Resmetirom Impurities
Daicel supplies resmetirom impurity standards supporting thyroid hormone receptor-β agonist development and impurity risk assessment.
References
FAQ's
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.
![2-(3,5-Dichloro-4-1,6-dihydro-5-1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione molecule](https://www.daicelpharmastandards.com/wp-content/uploads/2024/11/dcti-c-3893-900x600.png)
![2-[3,5-Dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl]oxy]phenyl]-3,5-dioxo-4H-[1,2,4]triazine-6-carboxylic acid molecule](https://www.daicelpharmastandards.com/wp-content/uploads/2024/10/dcti-c-3855-900x600.png)
![2-[3,5-Dichloro-4-[[6-chloro-5-(1-methylethyl)-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carbonitrile molecule](https://www.daicelpharmastandards.com/wp-content/uploads/2024/10/dcti-c-3854-900x600.png)
![2-3,5-Dichloro-4-1,6-dihydro-5-1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carboxamide molecule](https://www.daicelpharmastandards.com/wp-content/uploads/2024/11/dcti-c-3891-900x600.png)








